According to the issued ratings of 5 analysts in the last year, the consensus rating for zynerba pharmaceuticals stock is buy based on the current 5 buy ratings for zyne. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
In fact, when combining a zacks rank #3 or better and a positive earnings esp, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according.
Zyne stock forecast zacks. Mar 5, 2021 5:50pm est. Is a specialty pharmaceutical company which focuses on developing and commercializing proprietary. Find the latest zynerba pharmaceuticals, inc.
Zacks investment research downgraded shares of zynerba pharmaceuticals (nasdaq:zyne) from a buy rating to a hold rating in a research report report published on friday, zacks.com reports. Click to get this free report zynerba pharmaceuticals, inc. This signals that analyst sentiment is improving and the stock's earnings outlook is.
In fact, when combining a zacks rank #3 or better and a positive earnings esp, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according. Zynerba pharmaceuticals nasdaq updated dec 3, 2021 10:30 pm. According to zacks, zynerba pharmaceuticals, inc.
Click to get this free report zynerba pharmaceuticals, inc. Zyne | complete zynerba pharmaceuticals inc. Today, you can download 7 best stocks for the next 30 days.
Zyne zynerba pharmaceuticals — stock price and discussion | stocktwits. View all zacks #1 ranked stocks. This means that analyst sentiment is stronger and the stock's earnings outlook is.
Zyne is currently sporting a zacks rank of #2 (buy). Free stock analysis report to read this article on zacks.com click. Today, you can download 7 best stocks for the next 30 days.
Is currently rated as a zacks rank 3 and we are expecting an inline return from the zyne shares relative to the market in the. Z ynerba pharmaceuticals (zyne) closed at $4.15 in the latest trading session, marking a +1.47% move from the prior day. Zynerba pharmaceuticals (zyne) quote overview » charts » zynerba pharmaceuticals (zyne) price and consensus.
There are few to no technical positive signals at the moment. Article continues below advertisement zynerba’s stock forecast Zynerba pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is wednesday, march 9th, 2022 based off prior year's report dates.
Zacks' proprietary data indicates that zynerba pharmaceuticals, inc. This means that analyst sentiment is stronger and the stock's earnings outlook is. Earnings for zynerba pharmaceuticals are expected to decrease in the coming year, from ($1.07) to ($1.23) per share.
Free stock analysis report to read this article on zacks.com click. This change lagged the s&p 500's 0.73% gain on the day. Since then, zyne shares have decreased by 7.5% and is now trading at $3.60.
(zyne) stock quote, history, news and other vital information to help you with your stock trading and investing.
